Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Osamu_Okuda
|
| gptkbp:collaboratesWith |
gptkb:Roche
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:founded |
1925
|
| gptkbp:founder |
gptkb:Juzo_Ueno
|
| gptkbp:headquarters_location |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chugai Pharmaceutical
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:Nikkei_225
|
| gptkbp:netIncome |
213.1 billion yen (2022)
|
| gptkbp:notableProduct |
gptkb:Actemra
gptkb:Alecensa gptkb:Avastin gptkb:Hemlibra gptkb:Herceptin gptkb:Tarceva |
| gptkbp:numberOfEmployees |
7,529
|
| gptkbp:officialWebsite |
https://www.chugai-pharm.co.jp/english/
|
| gptkbp:parentCompany |
gptkb:Roche
|
| gptkbp:products |
pharmaceutical drugs
|
| gptkbp:researchInterest |
immunology
oncology bone and joint diseases renal diseases |
| gptkbp:revenue |
1,259.9 billion yen (2022)
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4519
|
| gptkbp:subsidiary |
gptkb:Roche
|
| gptkbp:bfsParent |
gptkb:罗氏
|
| gptkbp:bfsLayer |
5
|